Mok, Tony
Ladrera, Guia
Srimuninnimit, Vichien
Sriuranpong, Virote
Yu, Chong-Jen
Thongprasert, Sumitra
Sandoval-Tan, Jennifer
Lee, Jin Soo
Fuerte, Fatima
Shames, David S.
Klughammer, Barbara
Truman, Matt
Perez-Moreno, Pablo
Wu, Yi-Long https://orcid.org/0000-0002-3611-0258
Clinical trials referenced in this document:
Documents that mention this clinical trial
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer
https://doi.org/10.1016/j.lungcan.2016.04.023
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd., the Chinese Thoracic Oncology Group
Lung Cancer Research Group
This article is maintained by: Elsevier
Article Title: Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer
Journal Title: Lung Cancer
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.lungcan.2016.04.023
Content Type: article
Copyright: © 2016 The Authors. Published by Elsevier Ireland Ltd.